Trends in G-CSF Use in Geriatric Oncology: 2011 Afsos Sofog Survey

ABSTRACT Background Age is a risk factor for chemo-induced febrile neutropenia (FN). According international guidelines, it should be considered when discussing G-CSF use for regimens with FN risk between 10% and 20%. Prophylactic G-CSF remains controversial for regimens with a lower risk. Patients and methods A survey was undertaken in France to describe current treatment practices in patients aged 70 years and older with gynaecologic cancer. Individual data from 791 chemo-treated patients were collected (breast 74%, ovary 21%, uterus 5%, adjuvant 30%). Results According 101 practitioners, important factors to be considered for GCSF use are previous FN /neutropenic events (96%), bone radiotherapy (92%) or chemotherapy (86%), comorbidities (91%), performance status (PS) ≥2 (87%), recent septic event (92%), anemia (54%). In routine practice, GCSF was prescribed in 51% of the cases, ie 41% and 9% as primary and secondary prevention respectively and 0.4% in curative setting. Prophylactic GCSF prescription rates for regimens with FN risk ≥20%, 10-20% and Conclusion Our study suggests a trend to overtreatment in some cases, in comparison to international guidelines, and insufficient use of validated risk factors in treatment decision making. Disclosure C. Falandry: membership on an advisory board Chugai, I. Krakowski: membership on an advisory board Chugai, H. Cure: membership on an advisory board Chugai, E. Carola: membership on an advisory board Chugai, P. Soubeyran: membership on an advisory board Chugai, O. Guerin: membership on an advisory board Chugai, G. Freyer: membership on an advisory board Chugai